46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 54-55

46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

Background

Multifocal (MF) and multicentric (MC) breast cancers are known for their multiple tumor foci, posing distinct challenges in treatment and prognosis. The advent of advanced imaging techniques and treatment strategies calls for a reassessment of therapeutic approaches, specifically breast conserving therapy (BCT) vs mastectomy.

Objective

This study aims to consolidate and analyze recent data comparing the efficacy of BCT and mastectomy in the treatment of patients with MF/MC breast cancer, focusing on disease-free survival, local recurrence rates, and overall patient outcomes.

Methods

A thorough review of literature published from 2009 to October 2023 was conducted. The focus was on retrospective studies comparing outcomes of BCT vs mastectomy in patients with MF/MC breast cancer. A search was conducted using the PubMed database. The search strategy included the terms breast conserving surgery or breast conservation surgery, or breast conservation therapy and mastectomy and breast cancer, or breast neoplasm or multifocality, or multifocal or multicentric or multicentricity. The search included full-text studies published from 1976 to October 2023. A search of bibliographies of relevant publications was also conducted.

Inclusion and Exclusion Criteria

Inclusion:

  • Available in English or Spanish
  • Includes BCT and mastectomy as surgical interventions.

Exclusion:

  • Case reports
  • Case series
  • Review articles
  • Articles reporting on BCS or mastectomy that do not involve MF/MC breast cancer

Results

Local relapse rates: Studies, including those by Oh et al (2006) and Lim et al (2009), showed no significant difference in local relapse rates between BCT and mastectomy. For instance, Lim et al reported local relapse rates of 2% for BCT and 0.9% for mastectomy.

Survival rates: Kadioğlu et al (2014) found a 20% higher overall survival rate in patients undergoing BCS (92%) compared with mastectomy (72%). However, this was attributed to varying tumor characteristics.

Disease-free survival: Yerushalmi et al (2012)observed no statistically significant difference in 10-year disease-free survival between BCT and mastectomy, despite a slightly higher local relapse rate in the mastectomy group (5.8% vs 4.6% for BCT).

Comprehensive analysis: a 2023 study by Yu et al, utilizing the Surveillance, Epidemiology, and End Results database, indicated that specific patient groups might benefit more from mastectomy over BCT, based on factors such as age and tumor stage.

Conclusions

The current evidence supports the effectiveness of BCT, especially when complemented with radiotherapy and systemic therapy, for MF/MC breast cancer. Nevertheless, treatment choice should be tailored according to individual patient characteristics. These findings advocate for a more nuanced approach to MF/MC breast cancer treatment, moving beyond the historical bias toward mastectomy.

Articles in this issue

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content